By Ben Adams | FierceBiotech | October 29, 2019
Not a bad day’s work for Atlas-seeded startup Disc Medicine: It’s managed a healthy $50 million series A, led by Novo Nordisk’s VC arm, gained a new executive chair from Nimbus and nabbed a deal with AbbVie.
The Cambridge, Massachusetts-based biotech’s pipeline is focused on the hepcidin pathway, aimed at finding and working out new therapies against ineffective red blood cell production.
